

# Draft Genome Sequences of Two Extensively Drug-Resistant Strains of *Mycobacterium tuberculosis* Belonging to the Euro-American S Lineage

Lesibana A. Malinga,<sup>a,b</sup> Thomas Abeel,<sup>c,d</sup> Christopher A. Desjardins,<sup>c</sup> Talent C. Dlamini,<sup>e</sup> Gail Cassell,<sup>f</sup> Sinéad B. Chapman,<sup>c</sup> Bruce W. Birren,<sup>c</sup> Ashlee M. Earl,<sup>c</sup> Martie van der Walt<sup>a</sup>

South African Medical Research Council TB Platform, Pretoria, Gauteng, South Africa<sup>a</sup>; Department of Internal Medicine, University of Pretoria, Pretoria, Gauteng, South Africa<sup>b</sup>; Broad Institute, Cambridge, Massachusetts, USA<sup>c</sup>; Delft Bioinformatics Laboratory, Delft University of Technology, Delft, The Netherlands<sup>d</sup>; Medical Laboratory Sciences Department, Southern Africa Nazarene University, Manzini, Swaziland<sup>e</sup>; Harvard Medical School and Infectious Diseases Research Institute, Boston, Massachusetts, USA<sup>f</sup>

**We report the whole-genome sequencing of two extensively drug-resistant tuberculosis strains belonging to the Euro-American S lineage. The RSA 114 strain showed single-nucleotide polymorphisms predicted to have drug efflux activity.**

Received 11 January 2016 Accepted 11 January 2016 Published 3 March 2016

**Citation** Malinga LA, Abeel T, Desjardins CA, Dlamini TC, Cassell G, Chapman SB, Birren BW, Earl AM, van der Walt M. 2016. Draft genome sequences of two extensively drug-resistant strains of *Mycobacterium tuberculosis* belonging to the Euro-American S lineage. *Genome Announc* 4(2):e01771-15. doi:10.1128/genomeA.01771-15

**Copyright** © 2016 Malinga et al. This is an open-access article distributed under the terms of the [Creative Commons Attribution 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Address correspondence to Lesibana A. Malinga, lesibana.malinga@mrc.ac.za.

Drug-resistant tuberculosis (TB) caused by *Mycobacterium tuberculosis* is a global threat and a major public health problem in several countries (1). In South Africa, circulating *M. tuberculosis* strains are diverse (2), with three spoligotypes being most common: the Beijing spoligotype predominant in Western Cape, and the Euro-American LAM4 and S spoligotypes predominant in Gauteng and KwaZulu-Natal (KZN) provinces (3). The Euro-American S spoligotype (ST34) is prevalent in TB patients within KZN and Gauteng provinces (4).

We describe the draft genome sequences of two extensively drug-resistant (XDR) TB clinical strains of *M. tuberculosis* belonging to ST34. Permission to use these strains was granted by the University of Pretoria, Faculty of Health Sciences, Research Ethics Committee (206/2012). Both strains, RSA184 and RSA114, were isolated from patients from Swaziland. Spoligotyping and drug susceptibility testing (DST) were performed per standard protocols (5, 6).

DNA was extracted from heat-killed *M. tuberculosis* grown on slants, using a previously described chemical method (7). Illumina sequencing libraries were prepared as previously described (8) and sequenced using the Illumina HiSeq platform at the Broad Institute (Cambridge, MA, USA). Reads from RSA114 and RSA184 were assembled into draft genomes using ALLPATHS-LG with Pilon (9). The genome assemblies of 4,416,700 bp and 4,389,272 bp for RSA114 and RSA 184, respectively, were annotated by aligning each assembly to the H37Rv genome (CP003248.2) using Nucmer (10). For those genes not cleanly mapping to H37Rv, the protein-coding genes of 4,020 and 4,019 for RSA 114 and RSA 184, respectively, were predicted with Prodigal (9). Both strains had 45 tRNAs identified by tRNAscan-SE (11) and 3 rRNA genes predicted using RNAmmer (12). We also confirmed the experimental spoligotyping predictions using a previously described computational spoligotyping approach (13).

Sequence reads were aligned to the *M. tuberculosis* H37Rv ref-

erence genome using BWA (14), and Pilon was used to identify variants. We detected a total of 797 and 734 nonsynonymous changes relative to H37Rv for RSA114 and RSA184, respectively. We also detected nonsynonymous changes in *rpoB* (S450L, I491F), *katG* (S315T), and *gyrA* (D94G), previously implicated in drug resistance. Interestingly, RSA114, which lacked known resistance-conferring *gyrA* mutations, had 14, 7, and 4 nonsynonymous changes in genes encoding efflux pumps (EPs), phthiocerol dimycocerosates (PDIMs) and type VII secretion systems (ESXs), respectively. Drug resistance in *M. tuberculosis* can be acquired through mutations in EPs that increase their activity to expel a broad spectrum of antibiotics (15), and ofloxacin-resistant strains, lacking DNA gyrase mutations, were found to overexpress EPs (16). In RSA114, we identified mutations within the EP-encoding genes Rv0987, Rv2039c, and Rv0402c that are predicted by PROVEAN (<http://provean.jcvi.org/index.php>), to impact efflux activity. ESX export enzymes are involved in the synthesis of PDIM proteins, which have a role in virulence (17), and are overexpressed in XDR TB strains, suggesting a contribution to this XDR-level drug resistance (18). Future functional studies are needed to determine the impact of these mutations on drug resistance.

**Nucleotide sequence accession numbers.** The whole-genome sequences for RSA114 and RSA184 have been deposited at NCBI GenBank under the accession numbers [JKJF01000000](https://www.ncbi.nlm.nih.gov/nuccore/JKJF01000000) and [JKQQ01000000](https://www.ncbi.nlm.nih.gov/nuccore/JKQQ01000000), respectively.

## ACKNOWLEDGMENTS

This project has been funded in part with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under contract no. HHSN272200900018C and grant no. U19AI110818. L.A.M. received a PhD scholarship from the National Research Foundation. The funders played no role in collection, analysis, and interpretation of data; in the

writing of the manuscript; and in the decision to submit the manuscript for publication.

## FUNDING INFORMATION

This work, including the efforts of Lesibana Anthony Malinga, Christopher Desjardins, Gail Cassell, Sinead Chapman, Bruce Birren, Ashlee M. Earl, and Martie van der Walt, was funded by HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) (U19AI110818). This work, including the efforts of Lesibana Anthony Malinga, was funded by National Research Foundation (NRF).

The funders played no role in collection, analysis, and interpretation of data; in the writing of the manuscript; and in the decision to submit the manuscript for publication.

## REFERENCES

1. World Health Organization. 2014. Global tuberculosis report. World Health Organization, Geneva, Switzerland.
2. Streicher EM, Müller B, Chihota V, Mlambo C, Tait M, Pillay M, Trollip A, Hoek KG, Sirgel FA, Gey van Pittius NC, van Helden PD, Victor TC, Warren RM. 2012. Emergence and treatment of multidrug resistant (MDR) and extensively drug-resistant (XDR) tuberculosis in South Africa. *Infect Genet Evol* 12:686–694. <http://dx.doi.org/10.1016/j.meegid.2011.07.019>.
3. Chihota VN, Müller B, Mlambo CK, Pillay M, Tait M, Streicher EM, Marais E, van der Spuy GD, Hanekom M, Coetzee G, Trollip A, Hayes C, Bosman ME, Gey van Pittius NC, Victor TC, van Helden PD, Warren RM. 2012. Population structure of multi- and extensively drug-resistant *Mycobacterium tuberculosis* strains in South Africa. *J Clin Microbiol* 50:995–1002. <http://dx.doi.org/10.1128/JCM.05832-11>.
4. Gandhi NR, Brust JC, Moodley P, Weissman D, Heo M, Ning Y, Moll AP, Friedland GH, Sturm AW, Shah NS. 2014. Minimal diversity of drug-resistant *Mycobacterium tuberculosis* strains, South Africa. *Emerg Infect Dis* 20:426–433. <http://dx.doi.org/10.3201/eid2003.131083>.
5. Kamerbeek J, Schouls L, Kolk A, van Agterveld M, van Soolingen D, Kuijper S, Bunschoten A, Molhuizen H, Shaw R, Goyal M, van Embden J. 1997. Simultaneous detection and strain differentiation of *Mycobacterium tuberculosis* for diagnosis and epidemiology. *J Clin Microbiol* 35: 907–914.
6. Rüscher-Gerdes S, Pfyffer GE, Casal M, Chadwick M, Siddiqi S. 2006. Multicenter laboratory validation of the BACTEC MGIT 960 technique for testing susceptibilities of *Mycobacterium tuberculosis* to classical second-line drugs and newer antimicrobials. *J Clin Microbiol* 44: 688–692. <http://dx.doi.org/10.1128/JCM.44.3.688-692.2006>.
7. Somerville W, Thibert L, Schwartzman K, Behr MA. 2005. Extraction of *Mycobacterium tuberculosis* DNA: a question of containment. *J Clin Microbiol* 43:2996–2997. <http://dx.doi.org/10.1128/JCM.43.6.2996-2997.2005>.
8. Walker BJ, Abeel T, Shea T, Priest M, Abouelliel A, Sakthikumar S, Cuomo CA, Zeng Q, Wortman J, Young SK, Earl AM. 2014. Pilon: an integrated tool for comprehensive microbial variant detection and genome assembly improvement. *PLoS One* 9:e112963. <http://dx.doi.org/10.1371/journal.pone.0112963>.
9. Hyatt D, Chen GL, Locascio PF, Land ML, Larimer FW, Hauser LJ. 2010. Prodigal: prokaryotic gene recognition and translation initiation site identification. *BMC Bioinformatics* 11:119. <http://dx.doi.org/10.1186/1471-2105-11-119>.
10. Kurtz S, Delcher AL, Smoot M, Shumway M, Antonescu C, Salzberg S. 2004. Versatile and open software for compring large genomes. *Genome Biol* 5:R12. <http://dx.doi.org/10.1186/gb-2004-5-2-r12>.
11. Lowe TM, Eddy SR. 1997. tRNAscan-SE: a program for improved detection of transfer RNA genes in genomic sequence. *Nucleic Acids Res* 25: 955–964. <http://dx.doi.org/10.1093/nar/25.5.0955>.
12. Lagesen K, Hallin P, Rødland EA, Staerfeldt H-H, Rognes T, Ussery DW. 2007. RNAmmer: consistent and rapid annotation of ribosomal RNA genes. *Nucleic Acids Res* 35:3100–3108. <http://dx.doi.org/10.1093/nar/gkml60>.
13. Cohen KA, Abeel T, Manson McGuire A, Desjardins CA, Munsamy V, Shea TP, Walker BJ, Bantubani N, Almeida DV, Alvarado L, Chapman SB, Mvelase NR, Duffy EY, Fitzgerald MG, Govender P, Gujja S, Hamilton S, Howarth C, Larimer JD, Maharaj K, Pearson M, Priest M, Zeng Q, Padayatchi N, Grosset J, Young S, Wortman J, Mlisana K, O'Donnell M, Birren B, Bishai W, Pym A, Earl A. Evolution of extensively drug-resistant tuberculosis over four decades: whole genome sequencing and dating analysis of *Mycobacterium tuberculosis* isolates from KwaZulu-Natal. *PLoS Med* 12:e1001880. <http://dx.doi.org/10.1371/journal.pmed.1001880>.
14. Li H, Durbin R. 2010. Fast and accurate long-read alignment with burrows-Wheeler transform. *Bioinformatics* 26:589–595. <http://dx.doi.org/10.1093/bioinformatics/btp698>.
15. Vilchèze C, Jacobs WR, Jr. 2014. Resistance to isoniazid and ethionamide in *Mycobacterium tuberculosis*: genes, mutations, and causalities, p 431–453. In Graham F, Jacobs WR (ed), *Molecular genetics of Mycobacteria*, 2nd ed. ASM Press, Washington, DC. <http://dx.doi.org/10.1128/microbiolspec.MGM2-0014-2013>.
16. Louw GE, Warren RM, Gey van Pittius NC, Leon R, Jimenez A, Hernandez-Pando R, McEvoy CR, Grobbelaar M, Murray M, van Helden PD, Victor TC. 2011. Rifampicin reduces susceptibility to ofloxacin in rifampicin-resistant *Mycobacterium tuberculosis* through efflux. *Am J Respir Crit Care Med* 184:269–276. <http://dx.doi.org/10.1164/rccm.201011-1924OC>.
17. Mendum TA, Wu H, Kierzek AM, Stewart GR. 2015. Lipid metabolism and type VII secretion systems dominate the genome scale virulence profile of *Mycobacterium tuberculosis* in human dendritic cells. *BMC Genomics* 16:372. <http://dx.doi.org/10.1186/s12864-015-1569-2>.
18. Yu G, Cui Z, Sun X, Peng J, Jiang J, Wu W, Huang W, Chu K, Zhang L, Ge B, Li Y. 2015. Gene expression analysis of two extensively drug-resistant tuberculosis isolates show that two-component response systems enhance drug resistance. *Tuberculosis* 95:303–314. <http://dx.doi.org/10.1016/j.tube.2015.03.008>.